Pulaski County Attorney Martin Hatfield
Last week, Governor Andy Beshear signed into law a bill aimed at lowering prison populations by increasing the felony theft threshold for the first time in more than a decade.
Gov. Beshear signed the legislation on March 22. A correctional impact statement attached to the bill estimated its passage would save the state $4 million per year in prison costs alone.
Sponsored by Representative Ed Massey (R-Hebron), the House Chair of the Judiciary Committee, House Bill 126 raises the felony theft threshold from $500 to $1,000. Under current law, stealing anything worth $500 or more is a felony punishable by up to five years in prison. It additionally increases the threshold for several fraud-related crimes to $1,000 some of which currently have amounts as low as $100 for the offense to be a felony and allow police to charge members of organized shoplifting rings with a felony if a member stole a total of $1,000 worth of merchandise over 90 da
Print article At first, Andrew Christ was ecstatic. In soil taken from the bottom of the Greenland ice sheet, he’d discovered the remains of ancient plants. Only one other team of researchers had ever found greenery beneath the mile-high ice mass. But then Christ determined how long it had been since that soil had seen sunlight: Less than a million years. Just a blink of an eye in geologic terms. And it dawned on him. If plants once grew at multiple spots on the surface of Greenland, that meant the ice that now covers the island had entirely melted. And if the whole Greenland ice sheet had melted once in the not-so-distant past, that meant it could go again.
Merck s Bintrafusp Alph Monotherapy In Biliary Cancer Misses Threshold For Regulatory Filing
BERLIN (dpa-AFX) - Merck KGaA (MKGAY.PK) Tuesday announced a single agent efficacy second-line treatment using bintrafusp alpha monotherapy in locally advanced or metastatic biliary tract cancer or BTC patients. However, the study missed the pre-defined threshold that would have enabled regulatory filing for BTC in the second-line setting.
The study enrolled 159 patients, who have failed or are intolerant of first-line platinum-based chemotherapy.
The results demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up.
The company said the Phase II/III study of bintrafusp alfa in combination with chemotherapy is the first-line treatment for BTC.